Ligand Pharmaceuticals (LGND) Other Working Capital Changes (2010 - 2025)

Ligand Pharmaceuticals has disclosed Other Working Capital Changes across 16 years of filings, most recently posting -$285000.0 for Q2 2025.

• Other Working Capital Changes for Q2 2025 came in at -$285000.0, down 150.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$285000.0 (down 106.14% YoY), and the FY2025 annual result was -$578000.0, down 112.24% from the prior year.
• Other Working Capital Changes came in at -$285000.0 for Q2 2025 at Ligand Pharmaceuticals, up from -$293000.0 in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $9.6 million in Q4 2023 to a low of -$7.9 million in Q4 2022.
• The 5-year median for Other Working Capital Changes is $141500.0 (2021), against an average of $516722.2.
• Across the five-year window, Other Working Capital Changes soared 269.36% in 2021 and sank 3042.86% in 2022, its largest moves.
• Ligand Pharmaceuticals' Other Working Capital Changes stood at $914000.0 in 2021, then slumped by 968.16% to -$7.9 million in 2022, then jumped by 221.61% to $9.6 million in 2023, then slumped by 38.91% to $5.9 million in 2024, then plunged by 104.83% to -$285000.0 in 2025.
• The last three Other Working Capital Changes figures came in at -$285000.0 (Q2 2025), -$293000.0 (Q1 2025), and $5.9 million (Q4 2024), per Business Quant data.